[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of …
Y Tsukita, A Inoue - Japanese Journal of Clinical Oncology, 2022 - academic.oup.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
established as the standard first-line treatment for patients with previously untreated …
established as the standard first-line treatment for patients with previously untreated …
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
A Tartarone, R Lerose, C Lazzari, V Gregorc, M Aieta - Medical Oncology, 2014 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations derive greater benefits from first-and second-generation tyrosine kinase inhibitors …
mutations derive greater benefits from first-and second-generation tyrosine kinase inhibitors …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - Taylor & Francis
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Comparison between second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with non-small-cell lung …
S Mitsuya, K Tsuruoka, K Kanaoka… - Anticancer …, 2021 - ar.iiarjournals.org
Background: For epidermal growth factor receptor (EGFR)-mutated non-small cell lung
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges
Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for
patients with EGFR-mutated non-small cell lung cancer (NSCLC) has been shown to have …
patients with EGFR-mutated non-small cell lung cancer (NSCLC) has been shown to have …
Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
M Skrzypski, A Szymanowska-Narloch… - Contemporary …, 2017 - termedia.pl
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth
factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN …
factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN …
相关搜索
- meta analysis lung cancer
- japanese patients gefitinib erlotinib
- clinical efficacy gefitinib erlotinib
- japanese patients clinical efficacy
- retrospective comparison gefitinib erlotinib
- japanese patients retrospective comparison
- retrospective comparison clinical efficacy
- egfr mutation gefitinib and erlotinib
- egfr mutation lung cancer
- growth factor lung cancer
- survival benefits gefitinib and erlotinib
- clash of the generations lung cancer
- meta analysis comparison of gefitinib
- retrospective analysis lung cancer